Fit Life Peptides — Research Series
RETATRUTIDE 20MG
The Next-Generation Triple-Agonist Research Peptide
A synthetic research compound simultaneously targeting three hormonal receptor pathways. Featured in peer-reviewed Phase II clinical trial literature.
⚠ Important Disclaimer
This article is intended for educational and informational purposes only. Retatrutide is a research compound intended strictly for laboratory and scientific research use. It is not intended for human or animal consumption, self-administration, or therapeutic use, and has not been approved by the MHRA, FDA, or any other regulatory authority for such purposes. Nothing in this article constitutes medical advice. Any physiological effects referenced are based solely on preclinical and clinical research literature. Always consult a qualified healthcare professional regarding your health.
In the rapidly evolving landscape of research peptides, one compound has generated more sustained scientific interest than almost any other over the past two years. Retatrutide — also referenced in clinical literature as LY3437943 — is a next-generation synthetic peptide that simultaneously engages three distinct hormonal receptor pathways. That triple mechanism is what separates it from every earlier compound in the same research class.
Section 01
What Is Retatrutide?
Retatrutide is a synthetic peptide originally developed by Eli Lilly as part of their metabolic research programme. It functions as a triple receptor agonist, simultaneously activating:
GLP-1 Receptor
Glucagon-Like Peptide-1 — gut-derived, appetite and insulin signalling
GIP Receptor
Glucose-Dependent Insulinotropic Polypeptide — incretin synergy
Glucagon Receptor
Energy expenditure and thermogenic activity in preclinical models
This triple agonist profile is what the research community has been focusing on — no prior compound in this class has engaged all three pathways simultaneously, and the combination appears to produce compounding effects that exceed what any single pathway could achieve independently.
Section 02
How Does It Compare?
The evolution from single to dual to triple agonism has been the defining trajectory of this research class:
| Compound | GLP-1R | GIPR | Glucagon R | Class |
|---|---|---|---|---|
| Semaglutide | ✓ | ✗ | ✗ | Single Agonist |
| Tirzepatide | ✓ | ✓ | ✗ | Dual Agonist |
| Retatrutide ★ | ✓ | ✓ | ✓ | Triple Agonist |
Research comparison only. Not clinical guidance or treatment recommendation.
Section 03
The Triple Mechanism — Broken Down
① GLP-1 Receptor Agonism
GLP-1 is a hormone naturally secreted by intestinal L-cells in response to nutrient intake. In research models, GLP-1 receptor activation is associated with appetite regulation, slowed gastric emptying, and glucose-dependent stimulation of insulin secretion. GLP-1R agonism forms the foundation of the most intensively studied metabolic research compounds currently under clinical investigation.
② GIP Receptor Agonism
GIP — glucose-dependent insulinotropic polypeptide — is a complementary incretin hormone released primarily from duodenal K-cells. As an isolated mechanism, GIP has a modest research profile. The significant finding in dual and triple agonist research has been the apparent synergistic amplification when GLP-1R and GIPR are co-activated — the combined effect in preclinical models consistently exceeds what either agonist produces independently.
③ Glucagon Receptor Agonism — The Differentiator
The glucagon receptor component is what truly distinguishes Retatrutide from everything that came before it. Glucagon in isolation raises blood glucose via hepatic signalling. However, the key finding in triple agonist research is that when glucagon receptor engagement is combined with GLP-1R co-activation, the glycaemic-raising effect of glucagon is substantially blunted, while preclinical data suggests enhanced energy expenditure and thermogenic activity may be preserved. The net effect of glucagon receptor engagement in this combined context is the primary subject of ongoing research interest.
Section 04
What the Published Research Shows
The most significant publication to date is a Phase II clinical trial that appeared in the New England Journal of Medicine in 2023. The trial examined multiple dose cohorts over a 48-week period. At the highest dose cohort, reductions in body weight exceeded outcomes reported in equivalent-duration trials of earlier single or dual agonist compounds. Additional preclinical data has explored potential relevance to non-alcoholic fatty liver disease (NAFLD), cardiovascular risk factor modulation, and metabolic syndrome models.
Research Literature Highlights
Phase II
Clinical Trial Stage
48 wks
Trial Duration
3
Receptor Targets
NEJM
Publication
Research note: All data referenced was generated in controlled clinical trial settings with rigorous medical supervision and established research protocols. These findings do not constitute treatment claims of any kind.
Section 05
Quality & Specification
Retatrutide in a 20mg lyophilised format, to the following research specification:
Purity
99%
Third-party HPLC & MS verified
Format
20mg
Lyophilised powder, research vial
Storage
2–8°C
Refrigerated, light-protected
Reconstituted
28 days
Stable at 2–8°C post-reconstitution
Section 06
Reconstitution Reference (Research Use)
Standard Research Reconstitution Protocol
Solvent
Bacteriostatic Water (BW)
Option A — 2ml BW
10mg/ml concentration
Option B — 4ml BW
5mg/ml concentration
For qualified research personnel only. Prepare under sterile conditions. Not dosing guidance for human use.
Section 07
Frequently Asked Questions
Is Retatrutide legal to purchase in the UK?
Retatrutide is not a controlled substance under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016. It is sold as a research compound for laboratory use only. It is not licensed for human administration and is not sold for that purpose.
How does it differ from semaglutide or tirzepatide?
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates GLP-1 and GIP receptors. Retatrutide adds a third target — the glucagon receptor — making it the only triple agonist in this research class. This additional pathway and its interaction with the other two is the primary focus of ongoing research interest.
Where can I find the published trial data?
The Phase II trial data referenced in this article was published in the New England Journal of Medicine (2023) and is publicly available via NEJM.org and PubMed. Readers are encouraged to review primary sources independently.
⚠ Full Legal Disclaimer
This content is provided for educational and informational purposes only. Retatrutide is a research compound not intended for human or animal consumption, self-administration, or therapeutic use. It has not been evaluated or approved by the MHRA, FDA, or any other regulatory authority for diagnostic, therapeutic, or preventive use in humans or animals.
Nothing in this article constitutes medical advice, diagnosis, or treatment recommendation. Always consult a qualified healthcare professional. This compound must be handled exclusively within appropriate laboratory settings by qualified research professionals, in compliance with all applicable laws and regulations.
Written by
Khuram — Fit Life Peptides
Level 3 PT · CIMSPA Accredited · 28 Years Training Experience
www.fitlifeldn.co.uk
@fitlifeldn_